Insitro

insitro is a machine learning-driven drug discovery and development company based in South San Francisco, California, founded in 2018 by Daphne Koller. The company generates and aggregates large-scale, multimodal biological datasets and applies machine learning to them with the stated aim of building an integrated model of causal human biology and translating the resulting insights into therapeutics. Its public materials describe combining more than 20 petabytes of automated cellular experiment data with population-scale human genetics.

The company describes two named platform components. "Virtual Human" is presented as a genetically anchored causal AI engine built on an integrated corpus of human clinical and cellular data, used to identify causal disease targets before candidate optimization. "TherML" is described as a modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics, intended to match a modality to each target and indication. Earlier company communications framed the approach around three pillars: machine learning-enabled statistical genetics on deeply phenotyped human cohorts, predictive cell-based disease models, and machine learning-enabled therapeutics design.

As of a January 2024 report, insitro had more than 260 employees across 107,000 square feet of laboratory and office space and had raised more than $643 million in venture capital according to PitchBook. The company's pipeline has been described as spanning therapeutic areas including neuroscience and liver disease, advanced both internally and through partnerships.